Alpha Cancer Technologies develops therapies based on alpha-fetoprotein (AFP), the protein that maintains immune tolerance during pregnancy. We build our programs with partners — scientific, clinical, and commercial — and we welcome inquiries from companies interested in our platform and products.
ACT-101 — immunology (available for license)
ACT-101 is recombinant human alpha-fetoprotein (rHuAFP) — the only recombinant human AFP in clinical development. Developed through Phase II by Merrimack Pharmaceuticals, ACT-101 was dosed in more than 370 patients, with no serious adverse events attributable to the product and no neutralizing antibodies. Its pharmacology — modulation of myeloid-derived suppressor cells, dendritic-cell function, and T-cell responses — restores immune tolerance rather than suppressing immunity outright.
ACT is seeking a partner to license and develop ACT-101 in autoimmune and immunology indications, worldwide. Programs are development-ready in myasthenia gravis (FDA orphan drug designation) and ulcerative colitis (Phase II-ready, designed with Alimentiv).
ACT-903 — oncology
ACT-903 conjugates ACT-101 to a proprietary maytansine payload through a proprietary linker, targeting AFP-receptor-positive tumors. ACT-903 is preparing for clinic, with a first-in-human study planned at Princess Margaret Cancer Centre. ACT retains the oncology program and considers partnering discussions for development and commercialization.
Why partner with ACT
- The only recombinant human AFP platform — manufactured in E. coli at established scale, with a drug master file in place
- Human safety experience across more than 370 dosed patients
- Patent applications pending in the United States, Europe, Canada, China, and India, with coverage, if granted, to 2042 and beyond
- Clinical leadership at Princess Margaret Cancer Centre, Toronto
Contact
Richard Potts, Chair — rpotts@alpha-cancer.com